Technology
Health
Biotechnology

FibroGen

$55.96
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.28 (0.50%) Today
+$0.28 (0.50%) Today

Why Robinhood?

You can buy or sell FibroGen and other stocks, options, ETFs, and crypto commission-free!

About

FibroGen, Inc. engages in the discovery, development, and commercialization of therapeutics. It focuses on hypoxia-inducible factor and connective tissue growth factor biology to develop innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Read More The company was founded by Thomas B. Neff on September 29, 1993 and is headquartered in San Francisco, CA.

Employees
461
Headquarters
San Francisco, California
Founded
1993
Market Cap
4.76B
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
552.99K
High Today
$56.70
Low Today
$55.41
Open Price
$55.41
Volume
30.82K
52 Week High
$68.55
52 Week Low
$37.27

Collections

Technology
Health
Biotechnology
Therapy
Cancer Prevention
2014 IPO
US
North America

News

Seeking AlphaFeb 28

FibroGen, Inc. (FGEN) CEO Thomas Neff on Q4 2018 Results - Earnings Call Transcript

FibroGen, Inc. (NASDAQ:FGEN) Q4 2018 Earnings Conference Call February 27, 2019 5:00 PM ET Company Participants Karen Bergman - VP, IR & Corporate Communications Thomas Neff - Founder, Chairman & CEO Peony Yu - Chief Medical Officer Christine Chung - SVP, China Operations Elias Kouchakji - SVP Clinical Development, Drug Safety & Pharmacovigilance Pat Cotroneo - CFO Conference Call Participants Michael Yee - Jefferies Adam Walsh - Stifel, Nicolaus & Company Geoffrey Porges - SVB Leerink Joel Beat...

8
MarketBeatFeb 26

Stock Price, News, & Analysis for FibroGen

FibroGen, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; Pamrevlumab, a human-monoclonal antibody that inhibits the activity of connective tissue growth factor, which is in Phase II clinical deve...

2
Markets InsiderFeb 22

FibroGen Reports Fourth Quarter and Full Year 2018 Financial Results

SAN FRANCISCO, Feb. 22, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN), a leading biopharmaceutical company discovering and developing a pipeline of first-in-class therapeutics, today announced that it will report fourth quarter and full year 2018 financial results on Wednesday, February 27, 2019 after market close, and will host a conference call to discuss financial results and provide a business update at 5:00 p.m. ET (2:00 p.m. PT). Conference Call and Audio Webcast Interested parties may ac...

76

Earnings

-$0.59
-$0.32
-$0.04
$0.23
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 9, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.